Art

J-GLOBAL ID：201902229914483242   Reference number：19A0646637

Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study

慢性関節リウマチにおける生物学的疾患修飾抗リウマチ薬フリー寛解の達成に関連する因子:回答コホート研究【JST・京大機械翻訳】

Author (22)： Hashimoto Motomu (Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan) ,  Furu Moritoshi (Department of Orthopedic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan) ,  Yamamoto Wararu (Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan) ,  Yamamoto Wararu (Department of Health Information Management, Kurashiki Sweet Hospital, Kurashiki, Japan) ,  Fujimura Takanori (The Center for Rheumatic Diseases, Nara Medical University, Nara, Japan) ,  Hara Ryota (The Center for Rheumatic Diseases, Nara Medical University, Nara, Japan) ,  Katayama Masaki (Department of Rheumatology, Osaka Red Cross Hospital, Osaka, Japan) ,  Ohnishi Akira (Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan) ,  Akashi Kengo (Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan) ,  Yoshida Shuzo (Department of Internal Medicine (IV), Osaka Medical College, Osaka, Japan) ,  Nagai Koji (Department of Internal Medicine (IV), Osaka Medical College, Osaka, Japan) ,  Son Yonsu (First Department of Internal Medicine, Kansai Medical University, Osaka, Japan) ,  Amuro Hideki (First Department of Internal Medicine, Kansai Medical University, Osaka, Japan) ,  Hirano Toru (Department of Respiratory Medicine, Allergy and Rheumatic Disease, Graduate School of Medicine, Osaka University, Osaka, Japan) ,  Ebina Kosuke (Department of Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Osaka, Japan) ,  Uozumi Ryuji (Department of Biomedical Statistics and Bioinformatics, Graduate School of Medicine, Kyoto University, Kyoto, Japan) ,  Ito Hiromu (Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan) ,  Ito Hiromu (Department of Orthopedic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan) ,  Tanaka Masao (Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan) ,  Ohmura Koichiro (Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan) ,  Fujii Takao (Department of Rheumatology and Clinical Immunology, Wakayama Medical University, Wakayama, Japan) ,  Mimori Tsuneyo (Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan)
Material： Arthritis Research & Therapy (Web)
Volume： 20  Issue： 1  Page： 165  Publication year： 2018 
JST Material Number： U7412A  ISSN： 1478-6362  Document type： Article
Article type： 原著論文  Country of issue： United Kingdom (GBR)  Language： ENGLISH (EN)

Abstract/Point： Clinical remission can be main...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=19A0646637&from=J-GLOBAL&jstjournalNo=U7412A") }}

Thesaurus term： *rheumatoid arthritis ,  interleukin 6 ,  TNF receptor ,  glucocorticoid ,  polyethylene oxide ,  *remission ,  monoclonal antibody ,  drug therapy ,  TNF ,  CTLA-4 Antigen ,  *disease modifying antirheumatic drug
Semi thesaurus term： トシリズマブ ,  エタネルセプト ,  アバタセプト ,  インフリキシマブ ,  カットオフ値 , 【Automatic Indexing@JST】

Author keywords (4)： Rheumatoid arthritis ,  Biological disease-modifying antirheumatic drugs ,  Discontinuation ,  Tumor necrosis factor

JST classification (2)： Drug therapy(=pharmacotherapy)for musculoskeletal diseases  (GG05020D) ,  Clinical application of anti-inflammatory drugs  (GW15020E)

Reference (34)：

• Ann Rheum Dis; Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions; G Schett, P Emery, Y Tanaka; 75; 8; 2016; 1428-1437; 10.1136/annrheumdis-2016-209201; citation_id=CR1
• Arthritis Rheum; Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial; MA Quinn, PG Conaghan, PJ O'Connor; 52; 1; 2005; 27-35; 10.1002/art.20712; citation_id=CR2
• Ann Rheum Dis; Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study; M van den Broek, NB Klarenbeek, L Dirven; 70; 8; 2011; 1389-1394; 10.1136/ard.2010.147751; citation_id=CR3
• Clin Exp Rheumatol; The BeSt way of withdrawing biologic agents; CF Allaart, WF Lems, TW Huizinga; 31; 4 Suppl 78; 2013; S14-S18; citation_id=CR4
• Ann Rheum Dis; Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study; Y Tanaka, T Takeuchi, T Mimori; 69; 7; 2010; 1286-1291; 10.1136/ard.2009.121491; citation_id=CR5

Terms in the title (8)： 慢性関節リウマチ ,  生物学 ,  疾患修飾抗リウマチ薬 ,  寛解 ,  因子 ,  回答 ,  コホート ,  研究